Samir Patel, MD
Internal Medicine · Spotswood, NJNPI 1588659296
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,440 of the $2,993 with a category attached, or 81.5%. 25 manufacturers reported payments, led by AstraZeneca at 27.7% of the total. Reporting peaked in 2019 at $1,027 and has fallen 68.1% since, to $328 in 2025.
Across 165 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$829
- Cook Incorporated$474
- Novo Nordisk$301
- Johnson & Johnson$151
- Novartis$139
- Sanofi-aventis U.S. LLC$133
- plus $966 from 19 others
What the payments were for
- Travel & lodging$47416%
- Food & beverage$2,44082%
- Education$793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $829 |
| Cook Incorporated | 2 | $474 |
| Novo Nordisk | 21 | $301 |
| Johnson & Johnson | 11 | $151 |
| Novartis | 10 | $139 |
| Sanofi-aventis U.S. LLC | 5 | $133 |
| AbbVie(2 entities) | 8 | $113 |
| Astellas Pharma US Inc | 7 | $97 |
| Boehringer Ingelheim | 8 | $96 |
| Pfizer | 6 | $88 |
| Bayer | 6 | $87 |
| Lilly USA, LLC | 5 | $66 |
| Abbott | 4 | $60 |
| Amgen | 4 | $59 |
| Exact Sciences | 4 | $58 |
| Stryker | 2 | $44 |
| Amarin Pharma, Inc. | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Merck | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| GSK | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cook Medical CBDE$388
- BREZTRI$113
- FARXIGA$113
- LOKELMA$113
How this compares
$2,993 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 302 | $191,156 |
| OzempicSemaglutide | 110 | $153,138 |
| FarxigaDapagliflozin Propanediol | 172 | $146,353 |
| JardianceEmpagliflozin | 103 | $89,342 |
| EntrestoSacubitril/Valsartan | 91 | $47,643 |
| JanuviaSitagliptin Phosphate | 93 | $45,152 |
| XareltoRivaroxaban | 37 | $43,519 |
| TradjentaLinagliptin | 53 | $33,415 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $31,326 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $28,155 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $27,204 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $19,821 |
| LinzessLinaclotide | 12 | $18,396 |
| TrulicityDulaglutide | 13 | $16,746 |
| RetacritEpoetin Alfa-Epbx | 41 | $14,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Retacrit | $88 | $205,548343 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma, Symbicort | $829 | $177,207219 claims |
| Novo NordiskOzempic, Fiasp | $301 | $162,190139 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $96 | $129,456168 claims |
| MerckJanuvia, Janumet | $26 | $73,307112 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Shingrix | $14 | $63,224109 claims |
| Johnson & JohnsonXarelto, Procrit | $151 | $51,40648 claims |
| NovartisEntresto | $139 | $47,64391 claims |
| AbbVieLinzess | $113 | $18,39612 claims |
| Lilly USA, LLCTrulicity | $66 | $16,74613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Spotswood
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.